RefluxStop® Revolutionizes Treatment for Acid Reflux at EFS Meeting in Greece

Recently, at the European Foregut Society (EFS) Annual Meeting in Athens, Implantica AG proudly presented their groundbreaking device, RefluxStop®, which aims to tackle the widespread issue of acid reflux affecting over a billion individuals worldwide. The device attracted considerable attention from surgeons, gastroenterologists, and researchers gathered at the event to discuss advancements in treating foregut diseases.

The EFS meeting served as a significant platform where the latest developments in GERD treatments were exchanged. Attendees were particularly enthusiastic about the promising results showcased for RefluxStop®. The device addresses the root causes of gastroesophageal reflux disease (GERD), making it a compelling alternative to traditional treatments that often focus on symptom management rather than prevention.

During the symposium titled ‘RefluxStop for GERD: Excellent Long-Term Outcomes,’ approximately 100 medical professionals gathered to learn about new data reflecting the device's effectiveness. Esteemed experts such as Prof. Sebastian Schoppmann and Dr. med. Yves Borbély provided insightful discussions about the real-world results of the RefluxStop® device, emphasizing the transformative potential it holds for patients suffering from GERD.

Dr. Peter Forsell, the inventor of RefluxStop® and CEO of Implantica, expressed gratitude towards the panelists for their contributions. He noted, “With more than 1,400 patients treated across over 50 leading reflux centers in Europe and growing interest, it’s reassuring to see the international surgical community embracing RefluxStop®.